DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Ubicación actual:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

Eden Radioisotopes secures reactor project funding for medical isotope production

MILabs selected by Columbia University Irving Medical Center for upgrades to its molecular imaging capabilities

Blue Earth Diagnostics continues to expand access to Axumin (fluciclovine (18F)) in Europe

NRC calls for additional feedback on training and experience requirements for radiopharmaceuticals requiring a written directive

SHINE breaks ground on medical isotope production facility

MR Solutions' PET/MRI scanner explores innovative magnetic nanoparticles as a bimodal imaging agent

ITM builds new production site in Munich area

NorthStar Medical closes $100 million financing with Oberland Capital to expand domestic Mo-99 radioisotope production capacity

SNMMI and ACR collaborate on clinical data registry for nuclear medicine

New PET imaging biomarker could better predict progression of Alzheimer's disease

Zionexa completes a second $5 million capital raise

Press releases may be edited for formatting or style
New York, N.Y (USA) and Paris (France), April 11, 2019 – Zionexa, a radiopharmaceutical company specialized in the development and commercialization of innovative molecular imaging companion diagnostics (CDx) for targeted therapies in oncology, announced today that it has completed a second capital raise of $5 Million via two French investment funds, iXO Private Equity and SofiMac, as well as Denos, its majority shareholder.

This funding has been realized in line with Zionexa’s initial 2018 plan in order to raise a total of $10 Million with the first 12 months in order to register with the FDA (Food and Drug Administration), its first pipeline molecule, EstroTep, an innovative biomarker for targeted in-vivo diagnostic of metastatic breast cancer.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



These additional funds will also enable Zionexa to further develop its pipeline of other innovative molecules, notably with the launch of multicentric Phase III clinical trials in Europe that Zionexa will sponsor. A more significant third fundraising is planned within the next 12 months, to finance the commercial launches of EstroTep, in the U.S. and France.

Bernard Landes, CEO at Zionexa, comments: “This second fundraising will allow us to accelerate the launch of EstroTep and further develop our pipeline of targeted biomarkers for early and specific cancer diagnostic. Today, many patients follow heavy and often inadequate treatments. Our objective is to give clinicians access to innovative companion diagnostics tracers, in order for them to use these tracers in real life and contribute to improve the quality of their patient’s pathway. EstroTep, our first innovative companion diagnostic tracer has demonstrated its relevance in multiple clinical trials around the world.”

Baptiste Martin-Wurmser, Investment Director at IXO Private Equity adds:” Medical Imaging is a priority investment area for IXO Private Equity. Zionexa, specialized in molecular imaging, successfully develops new molecules that meet various needs: it helps clinicians better monitor patients’ disease and treatments, notably by evaluating their effectiveness. This has been key in our decision to invest in such an early stage project as well as the fact that we already knew the management team and its quality.”

Cécile Thébault, Associate Investments Director at Sofimac, further comments:” We are very glad to support this company which has key advantages in a high potential sector, especially in the U.S. Zionexa has an international and complementary team of experts, that bring a comprehensive know-how to the company, in terms of development, regulatory and market access of radiopharmaceuticals. Zionexa’s, ambitious pipeline, includes a first very promising molecule, EstroTep, that might be commercialized within 12 months.”
  Pages: 1 - 2 >>

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Anuncie
Aumente su conciencia de marca
Subastas + ventas Privadas
Consigue el mejor precio
Comprar Equipo/Piezas
Encuentra El Precio Más Bajo
Noticias diarias
Lee las últimas noticias
Directorio
Examina todos los usuarios DOTmed
Ética en DOTmed
Ver nuestro programa de ética
El oro parte programa del vendedor
Recibir las solicitudes de PH
Programa de distribuidor con servicio gold
Recibe solicitudes
Proveedores de atención de salud
Ver todos los HCP (abreviatura de asistencia médica) Herramientas
Trabajos/Entrenamiento
Encontrar/rellenar un trabajo
Parts Hunter +EasyPay
Obtener presupuestos para piezas
Certificado recientemente
Ver usuarios certificados recientemente
Recientemente clasificado
Ver usuarios certificados recientemente
Central de alquiler
Alquila equipos por menos
Vende equipos/piezas
Obtén más dinero
Mantenga el foro de los técnicos
Buscar ayuda y asesoramiento
Petición sencilla de propuestas
Obtén presupuestos para equipos
Feria comercial virtual
Encuentra servicio para el equipo
El acceso y el uso de este sitio está conforme a los términos y a las condiciones de nuestro AVISO LEGAL & AVISO DE LA AISLAMIENTO
Característica de y propietario DOTmeda .com, inc. Copyright ©2001-2019 DOTmed.com, Inc.
TODOS LOS DERECHOS RESERVADOS